专利汇可以提供Anthelmintic methods of use专利检索,专利查询,专利分析的服务。并且The thioallophanate compound represented by the following general formula ##EQU1## wherein X is hydrogen, chlorine atom, nitro or methyl group: Z is a substituting group selected from the group consisting of ##EQU2## and ##EQU3## has excellent anthelmintic activity and can be used for controlling helminthiasis of animals.,下面是Anthelmintic methods of use专利的具体信息内容。
What is claimed is:1. A method for the treatment of helminth infections in man and domestic animals which comprises administering to man or a domestic animal infected with helminths an anthelmintically effective amount of a benzene derivative selected from the group consisting of:2-(3-ethoxycarbonyl-2-thioureido)-N,N-dimethylaniline,2-(3-ethoxycarbonyl-2-thioureido)-N,N-dimethylaniline hydrochloride,1-(3-ethoxycarbonyl-2-thioureido)2-N,N-dimethyl-amino-benzene oxalate,1-formamido-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-acetamido-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-propionamido-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-cyclopropancarbonamido-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-benzamido-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-methoxycarbonamido-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-ethoxycarbonamido-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(3-n-propylureido)-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(3-n-butylureido)-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(3-n-butylureido)-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-thioformamido-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-(2-thiocarbamoyl-aminophenyl)-3-ethoxycarbonylthiourea,1-(3-ethoxycarbonyl-2-thioureido)-2-(3-methyl-2-thioureido)-benzene,1-(3-n-propyl-2-thioureido)-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-(3-N,N-dimethylamino-2-thiocarbonyl-2-thioureido)-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(3-N,N-dimethylaminothiocarbonyl-2-thioureido)-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-(3-N,N-dimethylamino-carbonyl-2-thioureido)-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-benzylidenamino-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(4-chlorobenzylidenamino)-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(4-methoxybenzylidenamino)-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(3-nitrobenzylidenamino-2-(3-ethoxycarbonyl-2-thioureido)-benzene,1-benzenesulfonicamido-2-(3-methoxycarbonyl-2-thioureido)-benzene,1-(4-toluenesulfonicamido)-2-(3-ethoxycarbonyl-2-thioureido)-benzene1(4-chlorobenzenesulfonicamodo)-2-(3-methoxycarbonyl-2-thioureido)-benzene,1. 2-bis(3-benzyloxycarbonyl-2-thioureido)-benzene,1.2-bis[3-(.beta.-methoxy) ethoxycarbonyl-2-thioureido]benzene,1.2-bis]3-(.beta.-chloroethoxycarbonyl)-2-thioureido]benzene,1.2-bis(3-allyloxycarbonyl-2-thioureido)benzene,1.2-bis[3-(2-propynyloxycarbonyl)-2-thioureido] benzene,1.2-bis[3-(4-chlorophenoxycarbonyl)-2-thioureido]benzene,1.2-bis[3-(4-nitrophenoxycarbonyl)-2-thioureido]benzene,1.2-bis[3-(4-methylphenoxycarbonyl)-2-thioureido]-4-chlorobenzene,3.4-bis[3-(4-chlorophenoxycarbonyl)-2-thioureido]-toluene,1.2-bis[3-(2-naphthoxycarbonyl)-2-thioureido]benzene and1.2-bis[3-(2-naphthoxycarbonyl)-2-thioureido]-4'-nitrobenzene.2. A method for the treatment of helminth infections according to claim 1 wherein the benzene derivative is administered orally.3. A method for the treatment of helminth infection in domestic animals according to claim 1 in which the benzene derivative is administered orally and wherein the dosage of the benzene derivative is from about 0.1 to 1000 mg. per Kg. of normal body weight.
DETAILED EXPLANATION OF THE INVENTION
This invention relates to compositions useful against helminthiasis and more particularly concerns anthelmintic compositions containing thioallophanate as ingredient.
Helminthiasis, the infestation of the body of domestic animals such as sheep, cattle, horses, goats, pigs, poultry, dogs and cats, by various species of parasitic worms, is perhaps the most common, most serious and most widespread disease in the world. Although the economic significance of this disease has led to extensive research for new and more effective anthelmintics, most of countermeasures developed to date have not been entirely satisfactory for one or more reasons; e.g. poor therapeutic index, specificity of action, high cost, low activity, limited anthelmintic spectrum.
According to this invention, it has been found that the specific thioallophanate compounds herein described possess a significant anthelmintic activity and can be effectively employed in the treatment and/or prevention of helminthiasis.
It is one object of the present invention to provide compositions containing such substances as an active anthelmintic ingredient. It is an additional object to provide methods of using them for the purpose of controlling helminthiasis. Further objects of the invention will become apparent from the following discussion of the invention.
According to the present invention, it has been surprisingly discovered that the thioallophanate compound represented by the following general formula (1) has excellent anthelmintic activity: ##EQU4## wherein X is hydrogen, chlorine atom, nitro or methyl group: Z is a substituting group selected from the group consisting of ##EQU5## and ##EQU6## R1 represents hydrogen atom or methyl group: R2 represents alkyl having not more than 12 carbon atoms, alkyl having not more than 3 carbon atoms substituted with halogen, methoxy or phenyl group, alkenyl having 3 carbon atoms which may be substituted with halogen atom, methoxy or phenyl group, alkynyl having 3 carbon atoms and aryl having not more than 10 carbon atoms which may be substituted with halogen atom, nitro or methyl group: R3 and R4 represent hydrogen atom or lower alkyl group respectively: R5 represents hydrogen atom, alkyl or cycloalkyl having not more than 4 carbon atoms, phenyl, alkoxy having not more than 4 carbon atoms, amino, alkylamino, 3,3-dimethyl-2-thioureido or 3,3-dimethylureido group: R6 and R7 represent hydrogen and chlorine atoms, methoxy, methyl or nitro group respectively: A represents inorganic acid or organic acid which is capable of forming a salt with an amino group: Y represents oxygen or sulfur atom: and n represents an integer of 0 - 3.
These compound can be prepared according to conventional processes. For example, the production process for the compound in which Z is ##EQU7## group was disclosed in the Patentblatt of German Pat. No. 1806123.9 issued on June 4, 1969 and the production process of other compounds were disclosed in the Patentblatt of German Pat. No. 1,930,540.9 issued on Jan. 8, 1970.
Typical examples of the thioallophanates which can be used in the present invention are listed in the Table 1.
Melting Point orNo. of DecomposionCompound Structural Formula Chemical Name Point (d) (°C)__________________________________________________________________________ SO ∥∥ 2-(3-Methoxycarbonyl-2-1 C--NH--C--O--CH3 thioureido)-aniline 184-185(d) SO ∥∥ 2-(3-Ethoxycarbonyl-2-2 C--NH--C--O--C2 H5 thioureido)-aniline 162-162.5(d) SO ∥∥CH3 2-(3-iso-Propoxy- C--NH--C--O--CH∠ carbonyl-2-thioureido) 137-1383 CH3 aniline SO 1-(2-Amino-4-methyl- ∥∥ phenyl)-3-methoxy- 167.5-168.5(d)4 C--NH--C--O--CH3 carbonyl-2-thiourea SO 1-(2-Amino-5-chlorophenyl)- ∥∥ 3-methoxycarbonyl-2- 182-182.5(d) NH--C--NH--C--O--C2 H5 thiourea NH2 SO 1-(2-Amino-5-nitrophenyl)- ∥∥ 3-methoxycarbonyl-2- 202-203(d)6 NH--C--NH--C--O--C2 H5 thiourea NH2 SO ∥∥ 2-(3-Methoxycarbonyl-2- NH--C--NH--C--O--CH3 thioureido)-aniline 153(d)e NH2.HNO3 SO ∥∥ NH--C--NH--C--O--CH3 2-(3-Methoxycarbonyl-2-8 NH2.COOH thioureido)-aniline 151.5-152(d) | COOH SO 2-(3-Ethoxycarboyl-2- ∥∥ thioureido)-aniline 188(d)9 NH--C--NH--C--O--C2 H5 hydrochloride NH2.HCl SO ∥∥ 2-(3-Ethoxycarbonyl-2-10 NH--C--NH--C--O--C2 H5 thioureido)-aniline 140.2-140.3(d) SO 2-(3-Ethoxycarbonyl- ∥∥ 2-thioureido)-aniline 140(d)11 NH--C--NH--C--O--C2 H5 oxalate SO 2-(3-Ethoxycarbonyl- ∥∥ 2-thioureido)-aniline 174(d)12 NH--C--NH--C--O--C2 H5 para-toluenesulfonate SO 2-(3-Ethoxycarbonyl- ∥∥ 2-thioureido)-N-methyl- 17113 C-- NH--C--O--C2 H5 aniline SO 2-(3-Ethoxycarbonyl- ∥∥ 2-thioureido)-N,N- 111-11314 NH--C--NH--C--O--C2 H5 dimethylaniline CH3 N∠ CH3 SO 2-(3-Ethoxycarbonyl-2- ∥∥ thioureido)-N,N-di- 167-168)d)15 CH3 methylaniline hydrochloride N∠. HCl CH3 S 1-(3-Ethoxycarbonyl-2- ∥ thioureido)2-N,N-dimethyl- 170-171 NHCNHCOOC2 H5 aminobenzene oxalate16 CH3 COOH N∠. | CH3 COOH SO ∥∥ 1-Formamido-2-(3- NH--C--NH--C--O--CH3 methoxycarbonyl-2- 185(d)17 thioureido)-benzene NH--C--H ∥ O SO ∥∥ 1-Acetamido-2-(3- NH--C--NH--C--O--CH3 methoxycarbonyl-2- 192.5-193.518 thioureido)-benzene NH--C--CH3 ∥ O SO ∥∥ 1-Propionamido-2-(3- NH--C--NH--C--O-- C2 H5 ethoxycarbonyl-2- 170-171.519 thioureido)-benzene NH--C--C2 H5 ∥ O 1-Cyclopropancarbonamido-20 2-(3-methoxycarbonyl-2- 191-192(d) thioureido)-benzene 1-Benzamido-2-(3-21 ethoxycarbonyl-2- 192-193 thioureido)-benzene SO ∥∥ 1-Methoxycarbonamido-2- NH--C--NH--C--O--C2 H5 (3-ethoxycarbonyl-2- 168-170(d)22 thioureido)-benzene NH--C--O--CH3 ∥ O SO ∥∥ 1-Ethoxycarbonamido-2- NH--C--NH--C--O--CH3 (3-methoxycarbonyl-2- 147-149(d)23 thioureido)-benzene NH--C--O--C2 H5 ∥ O SO ∥∥ 1-(3-n-Propylureido)-2- NH--C--NH--C--O--CH3 (3-methoxycarbonyl-2- 132.5-133.524 thioureido)-benzene NH--C--NH--C3 H7 ∥ O SO ∥∥ 1-(3-n-Butylureido)-2- NH--C-- NH--C--O--CH3 (3-methoxycarbonyl-2- 182-18325 thioureido)-benzene NH--C--NH--C4 H9 ∥ O SO ∥∥ 1-(3-n-Butylureido)-2- NH--C--NH--C--O--C2 H5 (3-ethoxycarbonyl-2- 18226 thioureido)-benzene NH--C--NH--C4 H9 ∥ O SO ∥∥ 1-Thioformamido-2-(3- NH--C--NH--C--O--C2 H5 ethoxycarbonyl-2- 17227 thioureido)-benzene NH--C--H ∥ O SO ∥∥ 1-(2-Thiocarbamoyl- NH--C--NH--C--O--C2 H5 aminophenyl)-3-ethoxy- 157(d)28 carbonylthiourea NH--C--NH2 ∥ S SO ∥∥ 1-(3-Ethoxycarbonyl-2- NH--C--NH--C--O--C2 H5 thioureido)-2-(3-methyl- 160-16129 2-thioureido)-benzene NH--C--NH--CH3 ∥ S SO ∥∥ 1-(3-n-Propyl-2-thioureido)- NH--C--NH--C--O--C2 H5 2-(3-ethoxycarbonyl-2- 132.5-133.5(d)30 thioureido)-benzene NH--C--NH--C3 H7 ∥ S S 1-(3-N,N-Dimethylamino-2- ∥ thiocarbonyl-2-thioureido)- NHCNHCOOCH3 2-(3-methoxycarbonyl-2- 149(d)31 CH3 thioureido)-benzene NHCNH--C--N∠ ∥∥CH3 SS SO ∥∥ 1-(3-N,N-Dimethylaminothio- NH--C--NH--C--O--C2 H5 carbonyl-2-thioureido)-2-32 CH3 (3-ethoxycarbonyl-2- 148-149(d) NH--C--NH--C--N∠ thioureido)-benzene ∥∥CH3 SS SO 1-(3-N,N-Dimethylamino- ∥∥ carbonyl-2-thioureido)- NH--C--NH--C--O--CH3 2-(3-methoxycarbonyl-2- 159-160(d)33 CH3 thioureido)-benzene NH--C--NH--C--N∠ ∥∥CH3 SO 1-Benzylidenamino-2-34 (3-methoxycarbonyl-2- 145-146 thioureido)-benzene 1-(4-Chlorobenzylidenamino)-35 2-(3-methoxycarbonyl-2- 183-183.5(d) thioureido)-benzene 1-(4-Methoxybenzyliden-36 amino)-2-(3-methoxycarbonyl- 159-159.5(d) 2-thioureido)-benzene 1-(3-Nitrobenzyliden-37 amino-2-(3-ethoxycarbonyl- 185(d) 2-thioureido)-benzene 1-Benzenesulfonicamido-2-38 (3-methoxycarbonyl-2- 197-198(d) thioureido)-benzene 1-(4-Toluenesulfonicamido)-39 2-(3-ethoxycarbonyl-2- 179-180(d) thioureido)-benzene 1-(4-Chlorobenzenesulfonic-40 amodo)-2-(3-methoxycarbonyl- 192-193(d) 2-thioureido)-benzene S ∥ 2(3-Allyloxycarbonyl-2-41 CNHCOOCH2 CH=CH3 thioureido)-aniline 138-139 SO ∥∥ NH--C--NH--C--O--CH3 1,2-Bis(3-methoxycarbonyl-42 2-thioureido)-benzene 181.5-182.5(d) - NH--C--NH--C--O-- CH3 ∥∥ SO SO ∥∥ NH--C--NH--C--O--C2 H5 1,2-Bis(3-ethoxycarbonyl-43 2-thioureido)-benzene 195(d) NH--C--NH--C--O--C2 H5 ∥∥ SO SO ∥∥ 1,2-Bis(3-isopropoxy- NH--C--NH--C--O--CH(CH3)2 carbonyl-2-thioureido)- 205-206(d)44 benzene NH--C--NH--C--O--CH(CH3)2 ∥∥ SO SO ∥∥ NH--C--NH--C--O--CH2 CH(CH3)2 1,2-Bis(3-isobutoxycarbonyl-45 2-thioureido)-benzene 197-198(d) NH--C--NH--C--O--CH2 CH(CH3)2 ∥∥ SO SO ∥∥ 3,4-Bis(3-ethoxycarbonyl- NH--C--NH--C--O--C2 H5 2-thioureido) toluene 175-176(d)46 NH--C--NH--C--O--C2 H5 ∥∥ SO SO ∥∥ 1,2-Bis(3-ethoxycarbonyl- NH--C--NH--C--O--C2 H5 2-thioureido)-4- 170.5-171.5(d)47 chlorobenzene NH--C--NH--C--O--C2 H5 ∥∥ SO SO ∥∥ 1,2-Bis(3-ethoxycarbonyl- NH--C--NH--C--O--C2 H5 2-thioureido)-4- 205-205.5(d)48 nitrobenzene NH--C--NH--C--O--C2 H5 ∥∥ SO SO ∥∥ 1,2-Bis(3-ethoxycarbonyl- NH--C--NH--C--O--C2 H5 2-thioureido)-4.5- 206-207(d)49 dichlorobenzene NH--C--NH--C--O--C2 H5 ∥∥ SO SO ∥∥ 1,2-Bis(3-ethoxycarbonyl- NH--C--NH--C--O--C2 H5 2-thioureido)-3,4,6- 180-18150 trichlorobenzen NH--C--NH--C--O--C2 H5 ∥∥ SO SO ∥∥ 1,2-Bis(3-benzyloxy- NH--C--NH--C--O--CH2 carbonyl-2-thioureido)- 171-17251 benzene NH--C--NH--C--O--CH2 ∥∥ SO SO ∥∥ 1,2-Bis[3-(-β-Methoxy) NH--C--NH--C--O--CH2 CH2 OCH3 ethoxycarbonyl-2-thioureido] 170.5-171.552 benzene NH--C--NH--C--O--CH2 CH2 OCH3 ∥∥ SO SO ∥∥ 1,2-Bis[3-(β-chloroethoxy- NH--C--NH--C--C--C2 H4 Cl carbonyl)-2-thioureido] 181-182(d)53 benzene NH--C--NH--C--O--C2 H4 Cl ∥∥ SO SO ∥∥ 1,2-Bis[(3-ethylthio)- NH--C--NH--C--S--C2 H5 carbonyl-2-thioureido] 191-192(d)54 benzene NH--C--NH--C--S--C2 H5 ∥∥ SO SO ∥∥ 1,2-Bis[3-dodecylthio) NH--C--NH--C--S--n-C12 H25 carbonyl]-thioureido- 122-123.5(d)55 benzene NH--C--NH--C--S--n-C12 H25 ∥∥ SO SO ∥∥ NH--C--NH--C--O--CH2 CH=CH2 1,2-Bis(3-allyloxycarbonyl-56 2-thioureido) benzene 166-167 NH--C--NH--C--O--CH2 CH=CH2 ∥∥ SO SO ∥∥ 1,2-Bis[3-(2-Propynyloxy- NH--C--NH--C--O--CH2 --C.tbd.CH carbonyl)-2-thioureido] 172-173(d)57 benzene NH--C--NH--C--O--CH2 --C.tbd.CH ∥∥ SO SO ∥∥ 1,2-Bis[3-(4-chlorophenoxy- NH--C--NH--C--O carbonyl)-2-thioureido] 193(d)58 benzene NH--C--NH--C--O ∥∥ SO SO ∥∥ 1,2-Bis[3-(4-nitrophenoxy- NH--C--NH--C--O carbonyl)-2-thioureido] 186(d)59 benzene NH--C--NH--C--O ∥∥ SO SO ∥∥ NH--C--NH--C--O 1,2-Bis[3-(4-methylphenoxy-60 carbonyl)-2-thioureido]- 191-192(d) NH--C--NH--C--O 4-chlorobenzene ∥∥ SO SO ∥∥ NH--C--NH--C--O-- 3,4-Bis[3-(4-chlorophenoxy-61 carbonyl)-2-thioureido]- 199-200(d) NH--C--NH--C--O-- toluene ∥∥ SO SO ∥∥ 1,2-Bis[3-(2-naphthoxy- NH--C--NH--C--O carbonyl)-2-thioureido] 191-192(d)62 benzene NH--C--NH--C--O ∥∥ SO SO ∥∥ 1,2-Bis[3-(2-naphthoxy- NH--O--NH--C--O carbonyl)-2-thioureido] 180(d)634'-nitrobenzene NH--O--NH--C--O ∥∥ SO 1-(3-Ethoxycarbonyl-2- throureido)-2-(3-ethoxy-64 carbonyl-1-methyl-2- 176-177(d) throureido)-benzene 1,2-Bis(3-ethoxycarbonyl-1-65 methyl-2-thioureido)benzene SO 1-(3-Ethoxycarbonyl-2- ∥∥ thioureido)-2-(3-methoxy- NH--C--NH--C--O--CH3 carbonyl-2-thioureido)- 177-178(d)66 benzene NH--C--NH--C--O--C2 H5 ∥∥ SO__________________________________________________________________________ note: Symbol (d) means decomposition
The above compound may be used in connection with any carrier vehicle and in the form of a solution, capsule, tablet or bolus.
Among the compounds employed as an ingredient of this invention, the salts (e.g. compound 7 ˜ 12, 15, 16) have high solubility in water and then they can be added to the drinking water just before use, or a drench formulation can be prepared in advance which may be diluted up to the desired concentration. When the composition of the present invention is in the form of solution, liquid media, e.g. alcohols, acetone, dimethyl sulfoxide, dimethylformamide, dioxane and cyclohexanone can be used. In the drench or solution preparation, concentrations may be 10% - 40% wt/vol. The exact percentage used will depend upon the dosage level required and the limitation imposed on the volume to be administered.
When administered in powdered form, the anthelmintic ingredient may be dispersed in or admixed with standard elements of animal sustenance, such as feed, or other orally ingestible carriers, such as distiller's dried grains, corn meal, alfalfa, ground oyster shells, molasses solubles, or corn cob meal. This method is generally used when it is desired to administer the compounds either as therapeutic or prophylactic use over an extended period.
When the composition is used in the solid dosage forms such as a capsule, tablet, or bolus, the ingredient may be conveniently mixed with any other acceptable vehicles including diluents, fillers, binders and lubricants in the preparation of such forms, and preferably materials nutritionally suitable such as starch, lactose, magnesium stearate, vegetable gums, hydroxy alkyl cellulose and the like.
The proportion of the anthelmintic ingredients in the above forms of administration may vary widely depending upon the desired dosage sought to be administered to the infected host. Thus, tablets and boluses, whether enteric in nature or not, can incorporate, for example, in the ranges from 5%, to 80% of the anthelmintic ingredient by weight of the total composition. Although the dosage rate varies depending on the mode of treatment, the activity of the components, the size of the host and the severity of infection, when single unit dosage forms such as tablets, boluses, or drenches are desired to be administered to the animal, suitable results are obtained when the compositions contain enough of the anthelmintic ingredients of the present invention to provide a dosage level of from 0.1 ˜ 1000 and preferably 5 ˜ 500mg/Kg of animal body weight.
If desired, the course of treatment may be extended over a period of days in which case the optimum daily dose level is reduced.
The following examples are given for the purpose of illustration only.
EXAMPLE 1
A bolus having the following composition suitable for oral administration was prepared.
______________________________________Compound (I) 10 parts by weightDicalcium phosphate 3 "Starch 1.5 "Gum 0.3 "Talc 1 "Mg stearate 0.1 "______________________________________
The dicalcium phosphate was thoroughly mixed with the compound I and the mixture was pulverized to a particle size of less than 90 mesh. 1 part of starch was added to the mixture in the form of an aqueous starch paste and the resulting mixture was granulated in the usual manner. The granules were dried at 50°C. The guar gum and the balance of the starch were added and the mixture thoroughly blended. The remainder of the ingredients were then added and the whole completely mixed and compressed.
EXAMPLE 2.
A drench having the following composition
Compound 2 10 parts by weightPolyoxyethylenealkylphenol ether 0.1 "Silicone oil 0.02 "Starch 15.0 "
was prepared by blending the ingredients into dry mix and the resulting mixture was added to 300ml. of water gradually.
EXAMPLE 3.
A drench having the following composition was prepared by usual formulating methods.
______________________________________Compound 4 10 parts by weightSilicone oil 0.02 "Hydroxy propylcellulose 1.2 "Water 150 "______________________________________
EXAMPLE 4.
Tablets having the following composition were prepared by the conventional process.
______________________________________Compound 25 10 parts by weightCalcium phosphate 8 "Hydroxypropylcellulose 1.5 "Lactose 80 "______________________________________
Hydroxypropylcellulose was dissolved into alcohol and the resulting solution was sprayed to the dry mix of the ingredients. After removing the solvent, the mixture was granulated in the usual manner and compressed to tablets having 0.2g of weight.
EXAMPLE 5.
Feed supplements according to the following compositions were prepared by the conventional process.
______________________________________(1) Compound 12 15Exoleated soybean 85(2) Compound 42 5Wheat bran 95(3) Compound 43 10Rice bran 90(4) Compound 44 25Corn grain 75______________________________________
EXAMPLE 6.
50 parts of compound 66 was mixed with 50 parts of tricalcium phosphate. Then the resulting powder was subdivided and loaded into hard gelatin capsules in such a manner that each capsule contains the equivalent of 200mg of the active ingredient.
EXAMPLE 7.
The anthelmintic ingredients listed in Table 2 were mixed with the dog food consisting of imitation meat. The dogs naturally infected with toxocara canis were divided into groups consisting of three dogs and after checking the number of eggs in 1g of excrement of each dog, the above food was fed in such manner that the each dog received 50mg of the anthelmintic ingredient/Kg of body weight/day for 3 days. Egg counts were made on the third day following the last treatment. Results are tabulated below in Table 2.
Table 2______________________________________ Eggs (average)Compound Dosage Before After Medication Medication______________________________________1 50mg/Kg/day 3,960 02 " 4,110 04 " 4,120 1608 " 3,780 09 " 3,900 013 " 4,100 17516 " 3,970 20517 " 4,250 018 " 4,080 3520 " 3,890 521 " 4,040 12522 " 3,770 1025 " 3,810 5027 " 4,200 3529 " 4,190 14530 " 3,920 21031 " 3,750 19033 " 4,150 20534 " 4,130 18035 " 3,920 7536 " 4,030 6538 " 4,050 539 " 3,860 041 " 4,260 5542 " 5,200 17543 " 4,850 056 " 5,150 18566 " 4,920 155Piperazine 200mg/Kg/day 4,780 535Control None 4,860 4,800______________________________________
No secondary effect or change on excrement, blood and appetite was observed.
EXAMPLE 8.
Oral administration of the anthelmintic ingredients as a drench according to the composition of Example 2 to sheep which were naturally infected with gastrointeslinal nematodes was performed for three days at levels of 50mg of the anthelmintic ingredient /Kg of body weight/day. A dose of the same ingredients was given to a group consisting of three sheep and the results of the egg count before and after third day of treatment are tabulated below in Table 3.
Table 3______________________________________ Eggs (average)Compound Dosage Before After Medication Medication______________________________________1 50mg/Kg/day 2,410 02 " 2,940 03 " 2,500 1205 " 2,050 806 " 2,420 1057 " 2,770 408 " 2,490 09 " 2,130 010 " 2,640 011 " 2,280 012 " 1,960 12513 " 2,500 14014 " 3,450 7515 " 2,750 16017 " 2,120 018 " 2,850 8019 " 1,970 10522 " 2,300 5523 " 2,570 11524 " 1,980 18025 " 3,080 7026 " 1,910 027 " 2,570 4028 " 3,110 7529 " 2,640 20530 " 2,530 034 " 2,010 16037 " 2,530 040 " 2,900 041 " 2,370 6042 " 2,470 043 " 1,990 044 " 3,250 11545 " 2,400 18046 " 2,540 12048 " 1,900 4549 " 2,690 16050 " 2,540 12551 " 3,080 8052 " 2,130 5553 " 2,440 054 " 1,970 19055 " 2,750 18056 " 3,100 12557 " 2,500 10058 " 2,200 059 " 2,450 8560 " 1,910 061 " 2,760 062 " 2,070 19063 " 2,430 9064 " 3,400 12565 " 2,290 4066 " 2,850 0Control None 2,280 2310" None 3,250 3010" None 2,890 2960______________________________________
No secondary effect or change on excrement, blood and appetite was observed.
标题 | 发布/更新时间 | 阅读量 |
---|---|---|
一种基于大数据算法的失陷主机检测技术 | 2020-05-13 | 556 |
作为抗微生物剂的增强剂的碳酸氢盐 | 2020-05-16 | 59 |
一种非线性动力学P2P网络蠕虫免疫预测方法 | 2020-05-17 | 589 |
杂环化合物、含有所述化合物的药物及其用途和其制备方法 | 2020-05-14 | 721 |
Nrf和HIF活化剂/HDAC抑制剂和使用其的治疗方法 | 2020-05-11 | 508 |
用于提高废水流出物和生物固体的质量的系统、方法和设备 | 2020-05-12 | 471 |
一种多功能网络安全态势感知系统 | 2020-05-15 | 402 |
免疫調節組成物及びその使用法 | 2020-05-08 | 349 |
BAMBAM:高スループット配列決定データの並列比較分析 | 2020-05-16 | 537 |
Sbiタンパク質を含む免疫原性組成物およびその使用 | 2020-05-12 | 389 |
高效检索全球专利专利汇是专利免费检索,专利查询,专利分析-国家发明专利查询检索分析平台,是提供专利分析,专利查询,专利检索等数据服务功能的知识产权数据服务商。
我们的产品包含105个国家的1.26亿组数据,免费查、免费专利分析。
专利汇分析报告产品可以对行业情报数据进行梳理分析,涉及维度包括行业专利基本状况分析、地域分析、技术分析、发明人分析、申请人分析、专利权人分析、失效分析、核心专利分析、法律分析、研发重点分析、企业专利处境分析、技术处境分析、专利寿命分析、企业定位分析、引证分析等超过60个分析角度,系统通过AI智能系统对图表进行解读,只需1分钟,一键生成行业专利分析报告。